Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications

Thrombosis Research

Volumn 95, Issue 2, 1999, Pages 75-82

  Holmes, Michael B ^a   Sobel, Burton E ^a   Howard, Diantha B ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Fibrinogen; Glycoprotein IIb IIIa; P selectin; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TRYPSIN INHIBITOR;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEGRANULATION; FIBRINOGEN METABOLISM; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; TITRIMETRY;

ASPIRIN; BLOOD PLATELETS; CORONARY DISEASE; FIBRINOGEN; HUMANS; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING;

EID: 0033565595     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00019-5     Document Type: Article

References (22)

1. Weiss H.J., Turitto V.T., Baumgartner H.R. Further evidence that glycoprotein IIb-IIIa mediates platelet spreading on subendothelium. Thromb Haemostas. 65:1991;202-205.
2. Shattil S.J., Hoxie J.A., Cunningham M., Brass L.F. Changes in the platelet membrane glycoprotein IIbIIIa complex during platelet activation. J Biol Chem. 260:1985;11107-11114.
3. Stenberg P.E., McEver R.P., Shuman M.A., Jacques Y.V., Bainton D.F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. Cell Biol. 101:1985;880-886.
4. Thiagarajan P., Tait J.F. Collagen-induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J Biol Chem. 266:1991;24302-24307.
5. Trip M.D., Cats V.M., van Capelle F.J.L., Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 322:1990;1549-1554.
6. Thaulow E., Erikssen J., Sandvik L., Stormorken H., Cohn P.F. Blood platelet count and function are related to total and cardiovascular death in apparently healthy man. Circulation. 84:1991;613-617.
7. Lam J.Y.T., Latour J.G., Lesperance J., Waters D. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol. 73:1993;333-338.
8. Schneider D., Tracy P.B., Mann K.G., Sobel B.E. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation. 96:1997;2877-2883.
9. Shattil S.J., Cunningham M., Hoxie J.A. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 70:1987;307-315.
10. Rand M.D., Lock J.B., van't Veer C., Gaffney D.P., Mann K.G. Blood clotting in minimally altered whole blood. Blood. 88:1996;1-14.
11. Xia Z., Wong T., Liu Q., Kasirer-Friede A., Brown E., Frojmovic M.M. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haemat. 93:1995;204-214.
12. Schneider D.J., Taatjes D.J., Howard D.B., Sobel B.E. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein. A potential contributor to cardiovascular risk JACC. 33:1999;261-266.
13. ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. ISIS-2 Lancet. 2(8607):1988;349-359.
14. Lewis H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med. 309:1983;396-403.
15. Antiplatelet Trialists' Collaboration Antiplatelet Trialists' collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Br Med J. 308:1994;81-106.
16. Roth G.J., Majerus P.W. The mechanism of the effect of aspirin on human platelets. J Clin Invest. 56:1975;624-632.
17. Zucker M.B., Peterson J. Inhibition of adenosine diphosphate induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proceedings of the Society of Experimental Biology and Medicine. 127:1968;547-551.
18. Ridker P.M., Cushman M., Stampfer M.J., Russell M.D., Tracy P.B., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
19. FitzGerald G.A., Tigges J., Barry P., Lawson J.A. Markers of platelet activation and oxidant stress in atherothrombotic disease. Thromb Haemostas. 78:1997;280-284.
20. Smitherman T., Milam M., Woo J., Willerson J. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia. Direct evidence for enhanced platelet reactivity in vivo Am J Cardiol. 48:1981;395-402.
21. Grande P., Grauholt A., Madsen J. Unstable angina pectoris. Platelet behavior and prognosis in progressive angina and intermediate coronary syndrome Circulation. Suppl(I)):1990;16-19.
22. Becker R., Tracy R., Bovill E.G., Mann K.G., Ault K. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Coronary Artery Disease. 5:1994;339-345.